Search

Displaying results 1231 - 1240 of 2435 in total
  1. Drug

    Azamulin

    go.drugbank.com/drugs/DB20304
    Experimental

    Azamulin is a small molecule drug. Azamulin has a monoisotopic molecular weight of 478.26 Da.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Burapitant

    go.drugbank.com/drugs/DB20607
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Burapitant is a neurokinin NK1​ (substance P) receptor antagonist. Burapitant has a monoisotopic molecular weight of 681.2 Da.

  3. Drug

    Cloperidone

    go.drugbank.com/drugs/DB20327
    Experimental

    Cloperidone is a small molecule drug. Cloperidone has a monoisotopic molecular weight of 398.15 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Mofarotene

    go.drugbank.com/drugs/DB20333
    Experimental

    Mofarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Mofarotene is a arotinoid derivative. Mofarotene has a monoisotopic molecular weight of 433.3 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Navamepent

    go.drugbank.com/drugs/DB21096
    Investigational

    Navamepent is a small molecule drug. Navamepent is under investigation in clinical trial NCT02329743 (Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery). Navamepent has a monoisotopi...

    Categories: P-glycoprotein inhibitors
  6. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bou...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all de...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, glicla...

    Synonyms: 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)ureaCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  10. Drug

    4-Methoxyamphetamine

    go.drugbank.com/drugs/DB01472
    ExperimentalIllicit

    Synonyms: P-methoxyamfetamine, P-methoxyamphetamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates